Mithra Announces 2020 Financial Calendar

/in , /by

Liege, Belgium, 15 January 2020 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company focused on women’s health, today announces its financial calendar for 2020 : 9 March 2020 : 2019 Full Year Results 22 April 2020 : 2019 Annual Report 22 May 2020 : Annual General Shareholders Meeting 24 September 2020 : 2020 […]

Read more →

E4 Paves the Road Towards a Revolutionary Era of Environmental Friendly Medicines

/in , /by

Estelle® to be the 1st Combined Oral Contraceptive (COC) based on an environmental friendly estrogen (E4) Environmental Risk Assessment study demonstrates absence of environmental risk for Estetrol (E4) E4 endocrine disruptive effects on the environment are insignificant in comparison to currently marketed estrogens commonly found in the aquatic environment E4 will contribute to preserve intact ground and […]

Read more →

Mithra Signs License and Supply Agreement for Commercialization of Tibelia® in Italy

/in , /by

Mithra grant a license to Farmitalia for commercialization of its hormone treatment Tibelia® in Italy Tibelia® is currently marketed in 13 countries through existing license and supply agreements Liege, Belgium, 07 January 2020 – 7 :30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into […]

Read more →

Mithra Signs LSA with Alvogen for Commercialization of Estelle® in Hong Kong and Taiwan

/in , /by

Mithra grants exclusive license to Alvogen for commercialization of its combined oral contraceptive Estelle® in Hong Kong and Taiwan Agreement follows licensing deals for Estelle® with market leaders in U.S., Europe, Russia, Canada, Brazil, Japan, South Korea, Middle East and South Africa Liege, Belgium, 6 January 2020 – 7 :30  CET – Mithra (Euronext Brussels: MITRA), a […]

Read more →

First patient recruited for Donesta® Phase III Clinical Study in Europe

/in , /by

Recruitment of the first patient for the second pivotal Donesta® Phase III study conducted in 12 countries in Europe, Russia and South America “E4 Comfort” Phase III Clinical Program for Donesta® successfully launched in October 2019 with recruitment of first patient for North American study Phase III Program aimed at enrolling approximately 2200 menopausal women […]

Read more →

Information on the Total Number of Voting Rights (Denominator)

/in , /by

Liege, Belgium, 24 December 2019 – 07:30 CET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Mithra Pharmaceuticals SA announces the following information, following the issuance of 1,444,250 new shares on 20 December 2019, in execution of the principle agreement concluded on 30 September […]

Read more →

Mithra Receives EUR 2.9 Million in Non-dilutive Funding

/in , /by

Liege, Belgium, 23 December 2019 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has been granted EUR 2.9 million in non-dilutive funding from the Walloon Region. The grant follows a decision by Mr Willy Borsus, Vice President of the Walloon Government and Minister of Economy, […]

Read more →

Mithra to Present at 38th Annual J.P. Morgan Healthcare Conference

/in , /by

Liege, Belgium, 19 December 2019 – 7:30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that Chief Executive Officer Mr. François Fornieri and members of the executive management team will be attending the 38th Annual J.P. Morgan Healthcare Conference in San Francisco from the 13th to the 16th of […]

Read more →

Mithra and Searchlight sign LSA for Myring™ in Canada

/in , /by

Mithra grants exclusive license for vaginal contraceptive ring to Searchlight Pharma for commercialization in Canada With Mithra’s two leading products Myring™ and Estelle®, Searchlight Pharma aims to further expand its growing footprint in Women’s Health Liege, Belgium, 16 December 2019 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today […]

Read more →

Mithra Signs LSA for Commercialization of Myring™ in Switzerland

/in , /by

Mithra grants license to Labatec for commercialization of vaginal contraceptive ring in Switzerland Production of Myring™ at the Mithra CDMO facility in Belgium Agreement follows licensing deals with major international market leaders for commercialization of Myring™ Liege, Belgium, 05 December 2019 – 7 :30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today […]

Read more →